Neumora Therapeutics (NMRA) reported a third-quarter 2026 net loss of $34.4 million, compared with a $56.8 million loss in the prior-year period. Net loss per basic and diluted share was $0.18, while cash and cash equivalents totaled $85.7 million as of September 30, 2026.
The clinical-stage biopharmaceutical company submitted an IND application to the U.S. Food and Drug Administration for NMRA-215, its oral NLRP3 inhibitor for obesity and cardiometabolic disease. It also reported multiple-ascending-dose expansion cohort results for NMRA-511.
- Third-quarter R&D expense was $22.6 million, versus $40.5 million a year earlier.
- Third-quarter G&A expense was $10.8 million, versus $12.2 million a year earlier.
- NMRA-511 at 30 mg twice daily showed dose-proportional exposure increases versus the 20 mg twice-daily dose and no serious adverse events in healthy elderly participants.
- The Phase 1 multiple-ascending-dose study of NMRA-898 in healthy volunteers and patients with stable schizophrenia remains ongoing.
$NMRA Insider Trading Activity
$NMRA insiders have traded $NMRA stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $NMRA stock by insiders over the last 6 months:
- DALJIT SINGH AURORA (See Remarks) has made 0 purchases and 11 sales selling 453,833 shares for an estimated $701,641.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NMRA Hedge Fund Activity
We have seen 67 institutional investors add shares of $NMRA stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PERCEPTIVE ADVISORS LLC removed 5,104,097 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $8,676,964
- EXOR N.V. added 4,215,662 shares (+inf%) to their portfolio in Q3 2026, for an estimated $2,513,377
- AFFINITY ASSET ADVISORS, LLC added 3,429,349 shares (+320.3%) to their portfolio in Q3 2026, for an estimated $2,044,577
- MILLENNIUM MANAGEMENT LLC removed 2,245,644 shares (-81.5%) from their portfolio in Q2 2026, for an estimated $3,817,594
- ORBIMED ADVISORS LLC added 2,139,882 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,637,799
- BOXER CAPITAL MANAGEMENT, LLC added 2,000,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,400,000
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,000,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,700,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.